A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
Public ClinicalTrials.gov record NCT02927769. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Risk-based, Response-adapted, Phase II Open-label Trial of Nivolumab + Brentuximab Vedotin (N + Bv) for Children, Adolescents, and Young Adults With Relapsed/Refractory (R/R) CD30 + Classic Hodgkin Lymphoma (cHL) After Failure of First-line Therapy, Followed by Brentuximab + Bendamustine (Bv + B) for Participants With a Suboptimal Response (CheckMate 744: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine whether nivolumab plus brentuximab vedotin (followed by brentuximab vedotin plus bendamustine in patient with suboptimal response) is safe and effective in treating patients with Hodgkin's lymphoma (cHL). Eligible patients are children, adolescents, and young adults relapsed or refractory to first line.
Study identification
- NCT ID
- NCT02927769
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 72 participants
Conditions and interventions
Conditions
Interventions
- Nivolumab Biological
- brentuximab vedotin Biological
- bendamustine Biological
Biological
Eligibility (public fields only)
- Age range
- 5 Years to 30 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 28, 2017 (Actual)
- Primary completion
- May 28, 2024 (Actual)
- Completion
- May 28, 2024 (Actual)
- Last update posted
- Feb 10, 2025
2017 – 2024
United States locations
- U.S. sites
- 43
- U.S. states
- 28
- U.S. cities
- 43
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Children's Hospital of Alabama | Birmingham | Alabama | 35233 | — |
| Phoenix Children'S Hospital | Phoenix | Arizona | 85016 | — |
| Loma Linda University Cancer Center | Loma Linda | California | 92350 | — |
| Valley Children's Hospital | Madera | California | 93636 | — |
| Children'S Hospital & Research Center At Oakland | Oakland | California | 94609 | — |
| Children'S Hospital Of Orange County | Orange | California | 92868 | — |
| Lucile Packard Children'S Research Hospital/Stanford Univ | Palo Alto | California | 94304 | — |
| Local Institution - 0091 | San Diego | California | 92109 | — |
| Childrens Hospital of Colorado | Aurora | Colorado | 80045 | — |
| Smilow Cancer Hospital At Yale New Haven Hospital | New Haven | Connecticut | 06520 | — |
| Nemours / A. I. duPont Hospital for Children | Wilmington | Delaware | 19803 | — |
| Children'S National Medical Center | Washington D.C. | District of Columbia | 20010 | — |
| Local Institution - 0062 | Jacksonville | Florida | 32207 | — |
| Local Institution - 0069 | St. Petersburg | Florida | 33701 | — |
| Children's Healthcare Of Atlanta | Atlanta | Georgia | 30322 | — |
| University Of Iowa | Iowa City | Iowa | 52242 | — |
| Local Institution - 0070 | Baltimore | Maryland | 21287 | — |
| Dana Farber Cancer Institute. | Boston | Massachusetts | 02215 | — |
| Local Institution - 0097 | Detroit | Michigan | 48201 | — |
| Local Institution - 0049 | Jackson | Mississippi | 39216 | — |
| Local Institution - 0085 | Kansas City | Missouri | 64108 | — |
| Washington University School Of Medicine | St Louis | Missouri | 63110 | — |
| Nevada Cancer Research Foundation | Las Vegas | Nevada | 89135 | — |
| Local Institution - 0067 | Hackensack | New Jersey | 07601 | — |
| Local Institution - 0047 | New Brunswick | New Jersey | 08903 | — |
| Local Institution - 0068 | Buffalo | New York | 14263 | — |
| Local Institution | Chapel Hill | North Carolina | 27599 | — |
| Carolinas Medical Center | Charlotte | North Carolina | 28203 | — |
| Cincinnati Children'S Hospital Medical Center | Cincinnati | Ohio | 45229-3039 | — |
| Local Institution - 0089 | Columbus | Ohio | 43205 | — |
| University Of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | 73104 | — |
| Local Institution - 0090 | Hershey | Pennsylvania | 17033-0850 | — |
| Childrens Hospital Of Philadelphia | Philadelphia | Pennsylvania | 19104 | — |
| Childrens Hospital Of Pittsburgh Of Upmc | Pittsburgh | Pennsylvania | 15224 | — |
| Vanderbilt University | Nashville | Tennessee | 37232-6310 | — |
| Local Institution - 0042 | Austin | Texas | 78723 | — |
| Local Institution - 0071 | Dallas | Texas | 75235 | — |
| Baylor College Of Medicine | Houston | Texas | 77030 | — |
| Primary Children's Hospital | Salt Lake City | Utah | 84113 | — |
| Children'S Hosp-Kings Daughter | Norfolk | Virginia | 23507-1910 | — |
| Virginia Commonwealth University | Richmond | Virginia | 23219 | — |
| Local Institution - 0048 | Seattle | Washington | 98105 | — |
| Local Institution - 0065 | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 36 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02927769, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 10, 2025 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02927769 live on ClinicalTrials.gov.